Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis

Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of case...

Full description

Bibliographic Details
Main Authors: V. M. Tsvetov, I. N. Sychev, D. A. Sychev
Format: Article
Language:Russian
Published: Izdatelstvo OKI 2020-10-01
Series:Качественная клиническая практика
Subjects:
Online Access:https://www.clinvest.ru/jour/article/view/524
_version_ 1797262078077042688
author V. M. Tsvetov
I. N. Sychev
D. A. Sychev
author_facet V. M. Tsvetov
I. N. Sychev
D. A. Sychev
author_sort V. M. Tsvetov
collection DOAJ
description Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks.
first_indexed 2024-04-24T23:51:23Z
format Article
id doaj.art-eefaef53ceca4ec982953d6774cca397
institution Directory Open Access Journal
issn 2588-0519
2618-8473
language Russian
last_indexed 2024-04-24T23:51:23Z
publishDate 2020-10-01
publisher Izdatelstvo OKI
record_format Article
series Качественная клиническая практика
spelling doaj.art-eefaef53ceca4ec982953d6774cca3972024-03-14T18:09:08ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732020-10-0104S394610.37489/2588-0519-2020-S4-39-46508Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysisV. M. Tsvetov0I. N. Sychev1D. A. Sychev2ФГБУ «Федеральный центр сердечно-сосудистой хирургии» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ГБУЗ ГКБ им. С.С. Юдина ДЗМФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииImpaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks.https://www.clinvest.ru/jour/article/view/524коронавирусхроническая почечная недостаточностьдиализcovid-19
spellingShingle V. M. Tsvetov
I. N. Sychev
D. A. Sychev
Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
Качественная клиническая практика
коронавирус
хроническая почечная недостаточность
диализ
covid-19
title Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
title_full Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
title_fullStr Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
title_full_unstemmed Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
title_short Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
title_sort use of etiotropic and pathogenetic medicines for covid 19 in patients with renal failure and or on dialysis
topic коронавирус
хроническая почечная недостаточность
диализ
covid-19
url https://www.clinvest.ru/jour/article/view/524
work_keys_str_mv AT vmtsvetov useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis
AT insychev useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis
AT dasychev useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis